Skip to Content


Active Substance: valdecoxib
Common Name: valdecoxib
ATC Code: M01AH03
Marketing Authorisation Holder: Pharmacia - Pfizer EEIG
Active Substance: valdecoxib
Status: Withdrawn
Authorisation Date: 2003-03-27
Therapeutic Area: Arthritis, Rheumatoid Osteoarthritis Dysmenorrhea
Pharmacotherapeutic Group: Antiinflammatory and antirheumatic products

Therapeutic Indication

Symptomatic relief in the treatment of osteoarthritis or rheumatoid arthritis.
Treatment of primary dysmenorrhoea.

The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risk (see sections 4.3, 4.4).

The marketing authorisation for Bextra has not been renewed by the marketing authorisation holder and is now withdrawn.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.